Author Interviews, Cancer Research, Lymphoma / 06.12.2019
Phase I Study of Duvelisib and Venetoclax in Relapsed or Refractory CLL / SLL
MedicalResearch.com Interview with:
[caption id="attachment_52370" align="alignleft" width="200"] Dr. Davids[/caption]
Dr. Matthew S. Davids MD MSC
Associate Director of the Dana-Farber CLL Center
Attending physician
Lymphoma Program, Division of Hematologic Malignancies
Dana-Farber
[caption id="attachment_52369" align="alignleft" width="150"]
Dr. Crombie[/caption]
Dr. Jennifer Crombie MD
Instructor in Medicine
Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: New data from our investigator-sponsored Phase 1 study exploring duvelisib in combination with venetoclax will be presented at ASH on December 7. In relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), duvelisib plus venetoclax demonstrated promising clinical activity, a manageable tolerability profile, and identified a recommended Phase 2 dosing (RP2D) regimen.
Dr. Davids[/caption]
Dr. Matthew S. Davids MD MSC
Associate Director of the Dana-Farber CLL Center
Attending physician
Lymphoma Program, Division of Hematologic Malignancies
Dana-Farber
[caption id="attachment_52369" align="alignleft" width="150"] Dr. Crombie[/caption]
Dr. Jennifer Crombie MD
Instructor in Medicine
Harvard Medical School
MedicalResearch.com: What is the background for this study?
Response: New data from our investigator-sponsored Phase 1 study exploring duvelisib in combination with venetoclax will be presented at ASH on December 7. In relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), duvelisib plus venetoclax demonstrated promising clinical activity, a manageable tolerability profile, and identified a recommended Phase 2 dosing (RP2D) regimen.